The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is launching a Women’s Health Programme to boost female participation in clinical trials.

Announced during the Drug Information Association (DIA)-MHRA Global Summit, taking place as part of London Life Sciences Week on 16 and 17 November, the MHRA notes that analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 highlighted that pregnant women were represented in just 1.1% of trials, while breastfeeding women were represented in 0.6%, showing a continued trend in representation gaps.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Despite making up 51% of the population, women continue to face gaps in research and treatment across a range of health conditions and have historically been underrepresented in clinical research, limiting the evidence available on medicines and medical devices during pregnancy and across reproductive health.

The Women’s Health Programme aims to address these challenges and explore how better data and scientific advancements can more accurately reflect women’s needs. 

Women’s health minister, Baroness Gillian Merron, said: “For too long, women’s health has been overlooked. Women make up more than half of our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on. That is not good enough, and we are determined to change it.

“This new programme is a welcome step. Together with our renewed Women’s Health Strategy, it will mean better evidence, better treatments, and a health system that listens to women and works for them.”

Pregnancy and other health conditions can impact how a patient responds to pharmaceuticals and medical devices, meaning research into how these patients are impacted is vital to ensure they can be used safely.

Michelle Riddalls OBE, CEO of PAGB, The Consumer Healthcare Association, said: “Better evidence can help women make more informed choices, as well as creating opportunities to widen access to appropriate treatments through the reclassification of medicines, supporting more women to manage their health through self-care. We welcome the MHRA’s ambition to ensure that the regulatory system continues to evolve with new evidence and supports appropriate innovation that can make a real difference to women’s health.”

This is not just an issue for the UK, however, as it is a global challenge to improve enrolment of pregnant women in clinical trials, with research showing they account for just 4% of patients in trials globally.

Earlier in 2026, Sheila Diamond, director of scientific engagement at Medidata, told Clinical Trials Arena that all stakeholders should be responsible for ensuring better access for pregnant and breastfeeding women in clinical trials.

Hopes for more scrutiny on FemTech

The MHRA reports that the UK’s FemTech sector has an annual turnover of nearly £300m ($396m), with technologies being developed across areas from reproductive health to long-term conditions and healthy ageing. 

David Hill, partner in healthcare and regulation at UK and Ireland law firm Browne Jacobson, said that, based on the UK’s diverse population, it should be “unimaginable” that there is a lack of sufficient evidence to ensure adequate access to diagnostics and treatments for women.

Hill said: “The MHRA’s Women’s Health Programme is a welcome step in plugging these gaps, but it will at some stage need to address a regulatory framework that is struggling to keep pace with FemTech innovation.

“FemTech covers a wide range of software, diagnostics and apps focused on women’s health, and the sector is growing rapidly. Yet regulation of software-based health tools – not just in the UK but globally – has not kept up with state-of-the-art technology that is advanced enough to actively intervene in a user’s health in a manner more akin to physical medical devices.”

Hill noted that apps with ‘tracking’ as their sole purpose fall outside the definition of a medical device, allowing companies too much “latitude to self-define their product as a ‘wellness’ tool and sidestep regulatory scrutiny”.